Pimagedine: Completed enrollment of 660 patients in a Phase III trial.

Alteon Inc. (ALTN), Ramsey, N.J. Product: Pimagedine, inhibitor of Advanced Glycosylation End-Products (A.G.E.s) Indication: Type I diabetes with kidney disease Status: Completed enrollment of 660 pat...